Delving into the Latest Updates on GDU-952 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target

AHR

Mechanism

AHR agonists(Aryl hydrocarbon receptor agonists)

Therapeutic Areas

Immune System DiseasesCongenital DisordersSkin and Musculoskeletal Diseases

Active Indication

Dermatitis, Atopic

Inactive Indication-

Originator Organization

Guangdong University of Technology

Active Organization

Guangdong University of Technology

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

The aryl hydrocarbon receptor (AhR) is widely expressed in the skin. It controls immune-mediated skin responses to various external environmental signals, promote terminal differentiation of epidermal keratinocytes and participates the maintenance of the skin barrier function. As a therapeutic target, AhR activation modulates many diseases progression driven by immune/inflammatory processes such as atopic dermatitis (AD) and psoriasis. In this study, we revealed that GDU-952 is a novel AhR agonist, which is able to decreases IgE serum levels, to inhibit pro-inflammatory cytokines such as IL-6 and TNF-α and to induce immunoregulatory effects through restoring Th1/Th2 immune balance and promoting CD4⁺FOXP3⁺regulatory T (Treg) populations in AD skin lesions. Furthermore, GDU-952 can strengthen the skin barrier function through upregulating epidermal differentiation-related and tight junction proteins. This may alleviate AD symptoms, such as dermatitis scores, epidermal hyperplasia and mast cell infiltration. These results offer a rationale for further preclinical/clinical studies to evaluate the possible use of GDU-952 in the management of AD.

100 Deals associated with GDU-952

Login to view more data